Prajakti A Kothare
Overview
Explore the profile of Prajakti A Kothare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Voss T, Kowalski K, Yang B, Kleijn H, Jones C, et al.
Clin Transl Sci
. 2019 Nov;
13(3):482-490.
PMID: 31758661
Ubrogepant (MK-1602) is a novel, oral, calcitonin gene-related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure-response...
2.
Dickmann L, Kothare P
Clin Pharmacol Ther
. 2019 Apr;
106(1):45-46.
PMID: 31013352
No abstract available.
3.
Dockendorf M, Murthy G, Bateman K, Kothare P, Anderson M, Xie I, et al.
Clin Pharmacol Ther
. 2018 Jun;
105(1):168-176.
PMID: 29885208
Merck & Co, Inc (Kenilworth, NJ) is investing in approaches to enrich clinical trial data and augment decision making through use of digital health technologies, outpatient sampling, and real-time data...
4.
Kothare P, Jadhav P, Gupta P, Harrelson J, Dickmann L
Clin Pharmacol Ther
. 2018 Apr;
104(6):1125-1135.
PMID: 29696625
Advances in emerging innovative technologies have led to optimistic outlooks on their transformative potential for healthcare and clinical trials. Given the increased attention, this white paper by the International Consortium...
5.
Li C, Dockendorf M, Kowalski K, Yang B, Xu Y, Xie I, et al.
J Clin Pharmacol
. 2017 Nov;
58(3):294-303.
PMID: 29136283
Merck & Co., Inc. (Kenilworth, New Jersey) has recently published an integrated strategy for implementation of dried blood spots (DBS) in late-stage trials for population pharmacokinetic (PK) modeling. We applied...
6.
Kothare P, Bateman K, Dockendorf M, Stone J, Xu Y, Woolf E, et al.
AAPS J
. 2016 Feb;
18(2):519-27.
PMID: 26857396
Dried blood spot (DBS) sample collection has gained increased interest across the pharmaceutical industry as a potential alternative to plasma for pharmacokinetic (PK) evaluations. However, regulatory guidelines and examples of...
7.
Prueksaritanont T, Chu X, Evers R, Klopfer S, Caro L, Kothare P, et al.
Br J Clin Pharmacol
. 2014 Mar;
78(3):587-98.
PMID: 24617605
Aims: Rosuvastatin and pitavastatin have been proposed as probe substrates for the organic anion-transporting polypeptide (OATP) 1B, but clinical data on their relative sensitivity and selectivity to OATP1B inhibitors are...
8.
Loghin C, Haber H, Beasley Jr C, Kothare P, Kauffman L, April J, et al.
Br J Clin Pharmacol
. 2012 Jul;
75(2):538-49.
PMID: 22803597
Aim: The effects of atomoxetine (20 and 60 mg twice daily), 400 mg moxifloxacin and placebo on QT(c) in 131 healthy CYP2D6 poor metabolizer males were compared. Methods: Atomoxetine doses...
9.
Kothare P, Seger M, Northrup J, Mace K, Mitchell M, Linnebjerg H
BMC Clin Pharmacol
. 2012 Mar;
12:8.
PMID: 22429273
Background: Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease...
10.
Iwamoto K, Nasu R, Yamamura A, Kothare P, Mace K, Wolka A, et al.
Endocr J
. 2009 Aug;
56(8):951-62.
PMID: 19706990
This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly (QW) in 30 Japanese patients with type 2 diabetes (T2D) suboptimally controlled by...